Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 17Lung Neoplasms 5Ovarian Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Esophageal Neoplasms 3Stomach Neoplasms 2Retinoblastoma 2Neoplasms 2Uterine Cervical Neoplasms 1Squamous-Cell Lung Cancer 1Retinal Neoplasms 1Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC) 1Resectable Non-small Cell Lung Cancer 1Resectable Lung Non-Small Cell Carcinoma 1Recurrence 1Pancreatic Neoplasms 1Ovarian Cancer Recurrent 1Oropharyngeal Neoplasms 1NSCLC 1Lymphatic Metastasis 1Liver Neoplasms 1Head and Neck Neoplasms 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Bronchogenic 1Carcinoma 1

Interventions

Cisplatin 101Radiotherapy 53Brachytherapy 41Paclitaxel 37Carboplatin 36Surveys and Questionnaires 28Blood Specimen Collection 20pembrolizumab 19Radiation 17Magnetic Resonance Spectroscopy 17Drug Therapy 17Colposcopy 16Bevacizumab 15Methods 14Early Intervention, Educational 12toripalimab 11Topotecan 11Radiotherapy, Intensity-Modulated 11Papanicolaou Test 11Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 11Chemoradiotherapy 11Biopsy 11camrelizumab 10Mass Screening 10Gemcitabine 10Patient Navigation 9Papillomavirus Vaccines 9Nivolumab 9Fluorodeoxyglucose F18 9Educational Status 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Uterine Cervical Neoplasms × Platinum Compounds × Clear all
NCT06986057 2025-05-22

Iparomlimab and Tuvonralimab Combined With Platinum-Based Chemotherapy for Neoadjuvant Treatment of Cervical Cancer

Shandong Tumor Hospital

Phase 2 Not yet recruiting
28 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡